IQVIA Holdings Inc.

NYSE:IQV

Medical - Diagnostics & Research

Healthcare
$257.84 -1.83%

-$3.13 today

Market cap
$42.49B
Beta
1.22
P/E (TTM)
20.4
EPS (TTM)
$8.22
52W Low $153.01High $247.05

Volume 1.40M

Average 1.62M

IQV Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

IQVIA Holdings Inc.NYSE: IQV

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How IQV compares with its peers on the latest reported figures

  • IQV's LTM Jun 2026 research & development of $0 is the 5th highest of the 9 companies compared; the peer median is $21.4M.
  • Research & development amounts to 0.0% of revenue for IQV, versus a peer median of 5.1%.
IQV Competitors Peer median
Research & Development for IQV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VEEVVeeva Systems Inc.LTM Jul 2026$821.92M +12.5%+13.8%23.8%
TEMTempus AI, Inc.LTM Sep 2026$327.05M +12.8%+25.3%21.7%
HCATHealth Catalyst, Inc.LTM Mar 2026$44.26M -24.0%-13.0%14.6%
CERTCertara, Inc.LTM Mar 2026$42.8M +20.1%+13.3%10.2%
IQVIQVIA Holdings Inc.LTM Jun 2026$0 ——0.0%
MEDPMedpace Holdings, Inc.LTM Sep 2026$0 ——0.0%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$0 ——0.0%
ICLRICON Public Limited CompanyLTM Jun 2026$0 ——0.0%
FTREFortrea Holdings Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding IQV) $21.4M+12.7%+13.6%5.1%

Competitors are the stored peer set for IQV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.87B14.41B14.98B15.41B16.31B
Cost of Revenue9.23B9.38B9.75B10.03B10.88B
Gross Profit4.64B5.03B5.24B5.38B5.43B
Gross Margin33.5%34.9%35.0%34.9%33.3%
Research & Development00000
Selling, General & Admin1.96B2.07B2.05B1.99B1.99B
Operating Expenses3.25B3.23B3.26B3.17B3.25B
Depreciation & Amortization1.26B1.13B1.13B1.11B640M
EBITDA2.77B2.91B3.26B3.45B2.94B
EBITDA Margin19.9%20.2%21.7%22.4%18.0%
Operating Income1.39B1.8B1.98B2.2B2.18B
Operating Margin10.0%12.5%13.2%14.3%13.4%
Interest Income6M13M36M47M45M
Interest Expense375M416M672M670M729M
Other Income / Expenses(259M)(448M)(518M)(533M)(569M)
Income Before Tax1.13B1.35B1.46B1.67B1.61B
Pre-Tax Margin8.2%9.4%9.7%10.8%9.9%
Income Tax Expense163M260M101M296M252M
Net Income966M1.09B1.36B1.37B1.36B
Net Margin7.0%7.6%9.1%8.9%8.3%
EPS (Basic)5.055.827.397.577.91
EPS (Diluted)4.955.727.297.497.84
Weighted Avg Shares191.4M187.6M183.8M181.3M171.9M
Weighted Avg Shares (Diluted)195M190.6M186.3M183.4M173.5M

IQVIA Holdings Inc.

NYSE:IQV

Intrinsic Alpha fair value

Locked

Current Price

$257.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.